

AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-49. (Canceled)

50. (Currently amended) A method for reducing restenosis following a vascular surgical procedure, the method comprising: locally administering to a human a biocompatible, non-biodegradable sustained release dosage form comprising a cytostatic amount of a free therapeutic agent dispersed in a ~~polymer-containing~~ polymer matrix, wherein said free therapeutic agent inhibits vascular smooth muscle cell migration, does not exhibit substantial cytotoxicity, and does not substantially inhibit protein synthesis.

51. (Previously presented) The method of claim 50, wherein the free therapeutic agent comprises taxol.

52. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises placement of a stent.

53. (Previously presented) The method of claim 50, wherein the vascular surgical procedure comprises angioplasty.

54. (Previously presented) The method of claim 50, wherein the locally administering comprises administering the free therapeutic agent directly to vascular smooth muscle tissue.

55. (Currently amended) The method of claim 50, wherein the ~~locally administering~~ release of the therapeutic agent from the dosage form occurs during or after the vascular procedure.